The clinical efficacy and safety of granulocyte and monocyte adsorptive apheresis in patients with Crohn's disease: A multicenter retrospective pilot study.
Crohn's disease
biologics
clinical response
granulocyte and monocyte apheresis
loss of response
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
02 Jan 2024
02 Jan 2024
Historique:
revised:
13
12
2023
received:
25
10
2023
accepted:
19
12
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
aheadofprint
Résumé
A remission induction therapy of granulocyte and monocyte adsorptive apheresis (GMA) was given to patients with Crohn's disease (CD). However, establishing an appropriate treatment strategy for GMA in patients with CD remains unclear. This study evaluated the clinical efficacy and subsequent clinical progression after GMA in patients with CD who underwent GMA in seven independent institutions in Japan from 2010 to 2023. Sixteen patients were enrolled. The overall remission and response rates were 25.0% and 68.8%, respectively. All patients responding to GMA received biologics that were continuously used and 36.4% of patients remained on the same biologics 52 weeks after GMA. Notably, all patients who continued the same biologics had previously experienced a loss of response to biologics. GMA may exhibit effectiveness even in cases with refractory CD. Moreover, it represents a potential novel therapeutic option for refractory CD with loss of response to biologics.
Identifiants
pubmed: 38168492
doi: 10.1111/1744-9987.14103
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 International Society for Apheresis and Japanese Society for Apheresis.
Références
Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389(10080):1741-1755. https://doi.org/10.1016/S0140-6736(16)31711-1
Qiu Y, Chen BL, Mao R, Zhang SH, He Y, Zeng ZR, et al. Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease. J Gastroenterol. 2017;52(5):535-554. https://doi.org/10.1007/s00535-017-1324-3
Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, et al. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol. 2011;163(1):50-58. https://doi.org/10.1111/j.1365-2249.2010.04279.x
Rodríguez-Lago I, Benítez JM, Sempere L, Sáez-González E, Barreiro-de Acosta M, de Zárate JO, et al. The combination of granulocyte-monocyte apheresis and vedolizumab: a new treatment option for ulcerative colitis? J Clin Apher. 2019;34(6):680-685. https://doi.org/10.1002/jca.21746
Song A, Jiang H, Guo L, Wu S. The combined efficacy of adalimumab with GMA method on the treatment of ulcerative colitis and repair of intestinal mucosal lesion. Am J Transl Res. 2021;13(5):5156-5164.
Ueno N, Sugiyama Y, Kobayashi Y, Murakami Y, Iwama T, Sasaki T, et al. Concomitant pharmacologic medications influence the clinical outcomes of granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis: a multicenter retrospective cohort study. J Clin Apher. 2023;38:406-421. https://doi.org/10.1002/jca.22040
Rodríguez-Lago I, Sempere L, Gutiérrez A, Núñez A, Leo Carnerero E, Hinojosa E, et al. Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis. Scand J Gastroenterol. 2019;54(4):459-464. https://doi.org/10.1080/00365521.2019.1600715
Yokoyama Y, Sawada K, Aoyama N, Yoshimura N, Sako M, Hirai F, et al. Efficacy of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease showing lost response to infliximab. J Crohns Colitis. 2020;14(9):1264-1273. https://doi.org/10.1093/ecco-jcc/jjaa051
Ozeki K, Tanida S, Mizoshita T, Tsukamoto H, Ebi M, Mori Y, et al. Combination therapy with intensive granulocyte and monocyte adsorptive apheresis plus adalimumab: therapeutic outcomes in 5 cases with refractory Crohn's disease. Case Rep Gastroenterol. 2012;6(3):765-771. https://doi.org/10.1159/000346312
Fukuda Y, Matsui T, Suzuki Y, Kanke K, Matsumoto T, Takazoe M, et al. Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study. J Gastroenterol. 2004;39(12):1158-1164. https://doi.org/10.1007/s00535-004-1465-z
Sands BE, Katz S, Wolf DC, Feagan BG, Wang T, Gustofson LM, et al. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. Gut. 2013;62(9):1288-1294. https://doi.org/10.1136/gutjnl-2011-300995
Yoshimura N, Yokoyama Y, Matsuoka K, Takahashi H, Iwakiri R, Yamamoto T, et al. An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease. BMC Gastroenterol. 2015;15:163. https://doi.org/10.1186/s12876-015-0390-3
Fukuchi T, Nakase H, Ubukata S, Matsuura M, Yoshino T, Toyonaga T, et al. Therapeutic effect of intensive granulocyte and monocyte adsorption apheresis combined with thiopurines for steroid- and biologics-naïve Japanese patients with early-diagnosed Crohn's disease. BMC Gastroenterol. 2014;13:124. https://doi.org/10.1186/1471-230X-14-124
Tanida S, Mizoshita T, Ozeki K, Katano T, Tanaka M, Nishie H, et al. Combination therapy with intensive granulocyte and monocyte adsorptive apheresis plus Ustekinumab in patients with refractory Crohn's disease. Ther Apher Dial. 2018;22(3):295-300. https://doi.org/10.1111/1744-9987.12697
Hibi T, Sameshima Y, Sekiguchi Y, Hisatome Y, Maruyama F, Moriwaki K, et al. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis. 2009;41(8):570-577. https://doi.org/10.1016/j.dld.2008.11.020
Yamamoto T, Iida T, Ikeya K, Kato M, Matsuura A, Tamura S, et al. A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis. Clin Transl Gastroenterol. 2018;9(7):170. https://doi.org/10.1038/s41424-018-0037-0 Erratum in: Clin Transl Gastroenterol. 2018 Oct 8;9(10):192. Erratum in: Clin Transl Gastroenterol 2018 Nov 14;9(11):205.
Ueno N, Sugiyama Y, Kobayashi Y, Murakami Y, Iwama T, Sasaki T, et al. Fecal calprotectin is a useful biomarker for predicting the clinical outcome of granulocyte and monocyte adsorptive apheresis in ulcerative colitis patients: a prospective observation study. BMC Gastroenterol. 2021;21(1):316. https://doi.org/10.1186/s12876-021-01889-0
Yokoyama Y, Kawai M, Fukunaga K, Kamikozuru K, Nagase K, Nogami K, et al. Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA. BMC Gastroenterol. 2013;13:27. https://doi.org/10.1186/1471-230X-13-27
Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55(3):426-431. https://doi.org/10.1136/gut.2005.069476
Ishiguro Y, Ohmori T, Umemura K, Iizuka M. Factors associated with the outcomes in ulcerative colitis patients undergoing granulocyte and monocyte adsorptive apheresis as remission induction therapy: a multicenter cohort study. Ther Apher Dial. 2021;25(4):502-512. https://doi.org/10.1111/1744-9987.13594